HIGHLIGHTS
- who: Zita Ku00e9pes et al. from the Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of, Nagyerdei St98, European Commission, Joint Research Centre (JRC), Karlsruhe, Germany have published the research work: Therapeutic Performance Evaluation of 213Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([213Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology, in the Journal: Pharmaceutics 2023, 15, 491. of 25/01/2023
- what: Since NGR-tripeptides (asparagine-glycine-arginine) selectively target neoangiogenesisassociated (APN/CD13) on cancer cells the authors aimed to evaluate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.